Navigation Links
Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has entered into an agreement to issue and sell in a private placement approximately 12 million shares of the Company's common stock and warrants to purchase up to approximately 6 million additional shares of the Company's common stock, for aggregate gross proceeds of approximately $86.6 million. The price to be paid for the common stock, $7.13 per share, is equal to the consolidated closing bid price on the Nasdaq Global Market on the day of pricing, February 13, 2009. The five-year warrants are exercisable at a price of $7.84 per share. The private placement is expected to close on February 18, 2009.

The financing was led by Venrock with participation by Frazier Healthcare Ventures, Domain Associates, Versant Ventures, New Enterprise Associates, Bay City Capital and T. Rowe Price Associates.

The securities to be sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and will be sold in a private placement pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Company has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors and shares of common stock issuable upon exercise of the warrants acquired by the investors.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualificati
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... IPSWICH, Mass. (PRWEB) June 01, 2015 ... decision support solutions, today introduced DynaMed Plus™ , ... and other medical professionals. It provides clinicians with the ... determine optimal patient care paths. , DynaMed Plus ... the market and includes the most frequently updated evidence-based ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 Note: ... new development in breast cancer prevention. , A phase ... suggests that postmenopausal women with ductal carcinoma in situ ... treatment and prevention. , The study (NSABP B-35/NRG Oncology) ... who completed the standard five-year treatment with tamoxifen to ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 There’s never a ... when it comes to non-emergency, minor illnesses. , As of ... 24/7 online access to medical care via the Internet. Patients ... smartphone, tablet or computer. , “Everyone is busy. We know ... a challenge, so we want to make it easier,” said ...
(Date:6/1/2015)... Texas (PRWEB) June 01, 2015 Carrick ... brain health landscape on a global level. This ... realms, allowing Carrick Brain Centers to broaden their scope ... healing. , Broadened horizons are accompanied by a restructuring ... 1, 2015, Carrick Brain Centers will separate itself from ...
(Date:6/1/2015)... 01, 2015 A University of ... inhibits signaling proteins that activate protein degradation, which ... exercise. 1 , The study published April ... male Spraque-Dawley rats 2-3 months of age who ... were given either whey protein (.4g/kg), low-dose Sustamine ...
Breaking Medicine News(10 mins):Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Carrick Brain Centers announces separation from Dr. Frederick Carrick to reflect the broader scope of impact and growth as an organization. 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3
... PRINCETON, N.J., July 15 Diabetes patients taking ... insulin in their pump for up to six days following ... labeling change, diabetes care company Novo Nordisk announced today.(1) The ... pump reservoir for two days. This makes NovoLog((R)) the first ...
... likely to keep education a priority, research finds , ... more likely than their Chinese counterparts to lose interest ... children outperform Americans in academic pursuits such as math, ... and Chinese students in grades 7 and 8, more ...
... , WASHINGTON, July 15 Steele will ... spelling out what Republicans are for and what they are against while ... care plan would do for ordinary Americans. , ... , The Senate Health, Education, Labor and ...
... 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) ... preparing for the tender business of 250,000 doses of ... can be viewed by visiting this web page directly ... batch exported to Indonesia this year by the company. ...
... WASHINGTON, July 15 Speaker Nancy Pelosi issued the following ... health care reform legislation: , , ... the Senate HELP Committee is further evidence of great momentum in ... of trying, this puts us one step closer to real reforms ...
... , Recent Death of Infant in ... SILVER SPRING, Md., July 15 The American Society for Parenteral ... the science and practice of nutrition support therapy, is saddened by the recent ... to him through an IV catheter and not through a feeding tube in ...
Cached Medicine News:Health News:FDA Approves NovoLog(R) Labeling Update 2Health News:FDA Approves NovoLog(R) Labeling Update 3Health News:FDA Approves NovoLog(R) Labeling Update 4Health News:U.S. Students' Academic Interests Tend to Wane in Middle School 2Health News:Hard To Treat Diseases (HTDS.PK) Tender Order To Indonesia 2Health News:Tube Feeding Error: Fatal Medical Mistakes 2Health News:Tube Feeding Error: Fatal Medical Mistakes 3
(Date:6/1/2015)... May 29, 2015 Research and Markets ... the "Global A Dialyzer Reprocessing Machine (A ... to their offering. The Global A ... Report 2014 is a professional and in-depth study ... reprocessing machine industry. The report provides a ...
(Date:6/1/2015)... CAMBRIDGE, Mass. , June 1, 2015  Boston ... compounds designed to target cancer stem cell (CSC) pathways, ... BBI608 and BBI503 in multiple tumor types at the ... in Chicago . Data ... an orally-administered investigational agent that targets STAT3, leading to ...
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
Breaking Medicine Technology:Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... NEW YORK , July 6 Reportlinker.com announces that a ... , , ... and leading players , , ... http://www.reportlinker.com/p0233961/Opportunities-in-Non-Surgical-Bio-Implants-Marketed-injectable-biomaterials-applications-and-leading-players.html , , , ...
... OXFORD, England and LANGHORNE, ... a transatlantic specialty pharmaceutical company focused on,oncology, pain control ... Japanese development and commercialization rights to its oncology therapy,Erwinase(R) ... product partnership EUSA has established in Japan . ...
Cached Medicine Technology:Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 2Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 3Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 4Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 5Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 6Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 7Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 8Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 9Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 10Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 11EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical 2EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical 3
The Shandon Linistain SLS Linear Stainer is an economical mid-size linear stainer for staining procedures that do not require heat....
... The Shandon Finesse E+ is ... provides automated specimen advance with ... balanced flywheel is easy to ... the user the option of ...
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
... is a service that directly connects ... the customers laboratory to the Thermo ... U.S.A., and Runcorn, U.K.* By using ... customer site, high-value support services are ...
Medicine Products: